An interventional study of Endovascular Therapy (Mechanical Thrombectomy) and Standard Medical Management in Stroke Acute, sponsored by Santiago Ortega Gutierrez. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Santiago Ortega Gutierrez · Not applicable, Interventional, and Treatment
The DONE SYMPLE Investigator-initiated phase III prospective, randomized, open-label, blinded endpoint-controlled clinical trial.
This clinical trial is a global clinical study testing whether a procedure called endovascular therapy, which removes blood clots from blocked brain arteries, can safely benefit more stroke patients when used up to 72 hours after symptoms begin. Endovacular Therapy is already proven to improve recovery in patients treated within 6 hours, but only when advanced imaging like Computed Tomography (CT) perfusion or Magnetic Resonance Imaging (MRI) is available to guide treatment. Unfortunately, many hospitals, specially in underserved areas, do not have access to this type of imaging.
This trial will investigate whether a basic brain scan called non-contrast CT, which is widely available in hospitals around the world, can be used instead. Special software will automatically analyze the CT scan to help doctors decide if a patient has enough brain tissue left to save with Endovascular Therapy. If this simpler approach works, it could expand access to lifesaving stroke care for more people globally.
The study will enroll 500 adult stroke patients, ages 18 to 80, with a large vessel blockage in the brain's anterior circulation, moderate to severe stroke symptoms, and who are between 6 and 72 hours from when they were last known to be well. All participants will undergo CT imaging analyzed by the automated software. If the scan shows a small core of already damaged brain tissue and a larger area of threatened but still viable brain, the patient will qualify.
Participants will be randomly assigned to receive either standard medical therapy alone or medical therapy plus Endovasculat Therapy which involves inserting a catheter through a blood vessel to reach the brain and using a device to remove the clot. This procedure is performed by trained stroke or neurointerventional specialists. The study is "open-label," meaning patients and doctors know which treatment is given, but the assessment of patient recovery will be done by independent reviewers who do not know the group assignments.
The primary goal is to determine if patients who receive Endovascular Therapy have better recovery at 90 days, measured by a scale called the modified Rankin Scale, which assesses how much disability a patient has after a stroke. The trial will also look at safety (especially brain bleeding after treatment), size and growth of brain injury on follow-up scans, recovery of strength and language, and overall quality of life and survival. Imaging will be reviewed centrally by a specialized team, and results will be analyzed to see how well Endovascular Therapy performs using this new patient selection method.
The DONE SYMPLE Trial is sponsored by Foundacio Ictus in Barcelona Spain and the University of Iowa is the Central Coordinating Center for the Study. It will take place at up to 20 hospitals worldwide. All patients will be followed closely with exams and imaging at specific time points up to 90 days after treatment.
If successful, this trial could change stroke care around the world by proving that Endovascular Therapy can be used safely and effectively even without advanced imaging, using tools available in most hospitals. This could help more stroke patients, especially in rural or resource-limited areas, access treatments that may improve their chances of recovery and reduce long-term disability.
The DONE SYMPLE Trial is a Phase III, multicenter, prospective, randomized, open-label trial with blinded endpoint assessment (PROBE design), evaluating the safety and efficacy of endovascular therapy (EVT) in patients with acute ischemic stroke (AIS) due to anterior circulation large vessel occlusion (LVO) treated between 6 to 72 hours from last known well. The key innovation is the use of non-contrast computed tomography (NCCT) with automated software analysis as the sole selection modality, replacing advanced imaging requirements such as CT perfusion or MRI diffusion-perfusion mismatch.
The trial addresses critical gaps in access to reperfusion therapy by enabling stroke triage and selection using standard NCCT imaging combined with artificial intelligence tools, thereby facilitating inclusion of centers without advanced imaging infrastructure. The selection criteria are based on automated estimation of ischemic core volume (≤70 cc) and evidence of LVO detection, derived from FDA-cleared deep learning algorithms and structured image analysis (e.g., ASPECTS quantification and vessel segmentation).
A total of 500 patients will be randomized 1:1 to either (1) standard medical therapy or (2) EVT plus standard medical therapy. Randomization will be stratified by baseline stroke severity (NIH Stroke Scale), time from symptom onset, core infarct volume, and enrolling site. EVT will be performed using CE-marked or FDA-cleared thrombectomy devices following standard institutional practice.
The primary endpoint is global disability at 90 days, assessed using the utility-weighted modified Rankin Scale (dw-mRS). Secondary efficacy analyses include mRS ordinal shift, dichotomized mRS (0-2), NIHSS change, and angiographic endpoints such as reperfusion success (TICI ≥2b) and first-pass effect (TICI 2c-3 on first attempt). Safety outcomes include symptomatic intracranial hemorrhage (sICH) per Heidelberg criteria, infarct growth on serial imaging, and all-cause mortality.
The statistical framework employs a Bayesian Gaussian model stratified by time-to-treatment intervals (6-24, 24-48, and 48-72 hours). The adaptive enrichment design enables interim analyses after enrollment milestones (n=200, 275, 350, 425) to evaluate futility, efficacy, or harm. The final sample size accounts for 10% potential LVO detection misclassification by automated software and 5% anticipated loss to follow-up.
Imaging is adjudicated centrally by a blinded core laboratory, ensuring uniform quantification of infarct volume and recanalization metrics. Functional outcomes are assessed by trained evaluators blinded to treatment allocation. Trial conduct is overseen by an independent data monitoring committee and a clinical events committee to adjudicate adverse events and outcomes.
By leveraging accessible imaging with automated tools, the DONE SYMPLE Trial aims to demonstrate that safe and effective EVT can be extended to patients beyond 24 hours and in settings without advanced imaging. If positive, the findings will inform future guideline updates and support broader implementation of thrombectomy in underserved populations globally.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 500 is above the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Santiago Ortega Gutierrez is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
18 to 80 years of age:
Ability to obtain signed or subject's Legally Authorized representative (LAR) has signed Consent form ***
Patients in the 6-24-hour after Last Known Well (LKW) may be enrolled only in centers where thrombectomy is not offered as standard of care due to the absence of advanced imaging capabilities.
In cases of discrepancy between the automated tool LVO detection and volume, and ASPECT Score or CTA judgment or Computed Tomography Angiography CTA findings, ASPECTS and CTA will take precedence.
Exclusion Criteria:
CT evidence of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive standard medical management for acute ischemic stroke plus endovascular therapy (mechanical thrombectomy). Treatment is initiated within 6 to 72 hours of stroke onset and is guided by automated non-contrast CT selection software.
Other: Endovascular Therapy (Mechanical Thrombectomy) · Other: Standard Medical Management
Participants in this arm will receive standard medical management for acute ischemic stroke without undergoing endovascular therapy. Treatment decisions are made according to institutional protocols and exclude mechanical thrombectomy.
Other: Standard Medical Management
Endovascular therapy performed with CE-approved thrombectomy devices, initiated within 6 to 72 hours after stroke onset in patients with anterior circulation large vessel occlusion. The procedure is guided by an automated non-contrast CT detection tool and follows standard device-specific instructions for use.
Standard medical management including therapies such as antiplatelet agents, anticoagulants, blood pressure control, and general supportive care. Delivered in accordance with institutional guidelines for acute ischemic stroke.
Global Disability at 90 Days
Global disability will be measured using the disability-weighted modified Rankin Scale (dw-mRS) at 90 days (±14 days) post-stroke. The dw-mRS is a validated tool that captures the severity of post-stroke disability across seven levels, ranging from no symptoms (0) to death (6). This outcome evaluates whether endovascular therapy (EVT) plus medical management results in superior functional outcomes compared to medical management alone in patients with anterior circulation large vessel occlusion (LVO) strokes treated between 6-72 hours after stroke onset and selected exclusively by automated non-contrast CT imaging.
Time frame: 90 days (±14 days)
Ordinal Distribution of the Modified Rankin Scale (mRS) at 90 Days
Global disability will be assessed using the full ordinal distribution of the Modified Rankin Scale (mRS), a 7-point scale that measures functional independence and global disability after stroke. The scale ranges from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores represent worse outcomes. For the purposes of this analysis, categories 5 (severe disability) and 6 (death) will be collapsed into a single category to enhance statistical robustness.
Time frame: 90 days (±14 days)
Proportion of Participants with Functional Independence (mRS 0-2) at 90 Days
Functional independence will be defined as achieving a score of 0 to 2 on the Modified Rankin Scale (mRS), a 7-point scale used to measure the degree of disability or dependence in daily activities following a stroke. The scale ranges from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. Scores of 0 to 2 reflect no symptoms, slight disability, or moderate disability with preserved independence.
Time frame: 90 days (±14 days)
Change in NIH Stroke Scale (NIHSS) Score at 24 Hours
Absolute change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours post-randomization. The NIHSS is a 42-point clinical scale used to assess neurological impairment in patients with stroke. Scores range from 0 to 42, with higher scores indicating greater stroke severity and worse neurological function. A decrease in NIHSS score represents clinical improvement.
Time frame: 24 hours (±16 hours)
Change in NIHSS Score at Day 5 or Discharge
Absolute change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to Day 5 (±1 day) post-randomization or hospital discharge, whichever occurs first. The NIHSS is a validated clinical scale ranging from 0 (no neurological deficit) to 42 (most severe deficit), with higher scores indicating more severe stroke-related impairment. A reduction in score reflects neurological improvement.
Time frame: 5 days (±1 day) or at discharge
Major Early Neurological Improvement at 24 Hours
Proportion of participants achieving either a ≥10-point reduction in NIHSS or an NIHSS score of 0-1 at 24 hours. This is a robust early marker of favorable prognosis.
Time frame: 24 hours (±16 hours)
Early Neurological Recovery at 24 Hours
Proportion of participants demonstrating early neurological improvement, defined as a ≥4-point reduction in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours post-randomization. The NIHSS is a standardized 42-point scale used to quantify neurological impairment following stroke, where scores range from 0 (no deficit) to 42 (maximum deficit). Higher scores indicate more severe impairment; thus, a decrease of 4 or more points reflects meaningful early neurological
Time frame: 24 hours (±16 hours)
Successful Angiographic Reperfusion
Defined as achieving modified Thrombolysis in Cerebral Infarction (mTICI) grade ≥2b at the end of the endovascular procedure, indicating adequate perfusion of the downstream territory.
Time frame: At the end of the endovascular procedure
First Pass Recanalization Rate
Proportion of patients achieving mTICI 2c or 3 on the first pass of the thrombectomy device in the intervention arm, a strong predictor of improved outcomes.
Time frame: Perioperative/Periprocedural
Workflow Efficiency Metrics
Quantitative time intervals including: door-to-CT, CT-to-arterial puncture, puncture-to-reperfusion, and puncture-to-final angiogram, used to assess procedural timeliness.
Time frame: From hospital arrival to procedure completion
Length of Inpatient Stay
Total number of days from admission to discharge from the index hospitalization.
Time frame: From hospital admission to discharge (up to 90 days post-randomization)
Discharge Disposition
Classification of discharge destination as home, acute rehabilitation, skilled nursing facility, long-term care, or other.
Time frame: At hospital discharge (up to 90 days post-randomization)
Health-Related Quality of Life (HRQoL) at 90 Days
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument, a validated patient-reported outcome measure that evaluates five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is rated on a 5-point scale (1 = no problems; 5 = extreme problems). Responses are used to generate an index value ranging from less than 0 (states worse than death) to 1 (full health), with higher scores indicating better health-related quality of life.
Time frame: 90 days (±14 days)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santiago Ortega Gutierrez